The FDA is convening an expert panel in July to consider whether compounding pharmacies can manufacture unproven peptides that lack thorough clinical testing, a decision that aligns with Health Secretary RFK Jr.'s stated support for peptide access. The peptide market is growing among wellness influencers and athletes despite expert warnings about safety risks and lack of rigorous testing, with most products sourced from unregulated compounding pharmacies or international providers. RFK Jr. frames the FDA panel as restoring 'regulated access' and shifting demand from the black market, but the underlying substances remain largely untested for safety and efficacy in human populations.